title: Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
abstract: We analysed viral kinetics from a 2-day treatment with BILN 2061, a serine protease inhibitor of hepatitis C virus, in patients chronically infected with genotype 1 hepatitis C virus. The efficiency (E), describing inhibition of viral production, was above 99.45% in all patients with minor or moderate fibrosis receiving doses of 200mg and 500 mg twice daily and larger than in previous studies for interferon-based treatments. However, epsilon was slightly smaller in patients with cirrhosis given 200mg and markedly smaller in patients given 25 mg. Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments.
authors.affiliation: Medizinische Klinik und Poliklinik, Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. Eva.Herrmann@Uniklinikum-Saarland.de
authors.forename: Eva
authors.initials: E
authors.lastname: Herrmann
authors.forename: Stefan
authors.initials: S
authors.lastname: Zeuzem
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
authors.forename: Holger
authors.initials: H
authors.lastname: Hinrichsen
authors.forename: Yves
authors.initials: Y
authors.lastname: Benhamou
authors.forename: Michael P
authors.initials: MP
authors.lastname: Manns
authors.forename: Markus
authors.initials: M
authors.lastname: Reiser
authors.forename: Henk
authors.initials: H
authors.lastname: Reesink
authors.forename: José L
authors.initials: JL
authors.lastname: Calleja
authors.forename: Xavier
authors.initials: X
authors.lastname: Forns
authors.forename: Gerhard G
authors.initials: GG
authors.lastname: Steinmann
authors.forename: Gerhard
authors.initials: G
authors.lastname: Nehmiz
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D019540:Area Under Curve; D002219:Carbamates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D007700:Kinetics; D047028:Macrocyclic Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D011804:Quinolines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; C479555:BILN 2061; D002219:Carbamates; D016898:Interferon-alpha; D047028:Macrocyclic Compounds; D011804:Quinolines; D012367:RNA, Viral; D015842:Serine Proteinase Inhibitors; D013844:Thiazoles